The Duffy antigen receptor for chemokines regulates asthma pathophysiology

Publication Type:
Journal Article
Citation:
Clinical and Experimental Allergy, 2017, 47 (9), pp. 1214 - 1222
Issue Date:
2017-09-01
Metrics:
Full metadata record
Files in This Item:
Filename Description Size
Chapman_et_al-2017-Clinical_%26amp%3B_Experimental_Allergy.pdfPublished Version1.19 MB
Adobe PDF
© 2017 John Wiley & Sons Ltd Background: The Duffy antigen receptor for chemokines (DARC) is an atypical receptor that regulates pro-inflammatory cytokines. However, the role of DARC in asthma pathophysiology is unknown. Objective: To determine the role of DARC in allergic airways disease in mice, and the association between DARC single nucleotide polymorphisms (SNPs) and clinical outcomes in patients with asthma. Methods: Mice with targeted disruption of the Darc gene (Darc∆E2) or WT mice were challenged over 3 weeks with house dust mite (HDM) antigen. Allergic airways disease was assessed 24 hours and 7 days following the final challenge. Additionally, associations between DARC SNPs and clinical outcomes were analysed in a cohort of poorly controlled asthmatics. Results: Total airway inflammation following HDM did not differ between Darc∆E2 and WT mice. At 24 hours, Darc∆E2 mice had increased airway hyperresponsiveness; however, at 7 days airway hyperresponsiveness had completely resolved in Darc∆E2 but persisted in WT mice. In poorly controlled asthmatics, DARC SNPs were associated with worse asthma control at randomization and subsequent increased risk of healthcare utilization (odds ratio 3.13(1.37-7.27), P=.0062). Conclusions and Clinical Relevance: Our animal model and human patient data suggest a novel role for DARC in the temporal regulation in asthma pathophysiology and symptoms.
Please use this identifier to cite or link to this item: